- Home
- MIRM vs LU Comparison
MIRM vs LU Comparison
Compare MIRM & LU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- LU
- Stock Information
- Founded
- MIRM 2018
- LU 2005
- Country
- MIRM United States
- LU China
- Employees
- MIRM N/A
- LU N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- LU Finance: Consumer Services
- Sector
- MIRM Health Care
- LU Finance
- Exchange
- MIRM Nasdaq
- LU Nasdaq
- Market Cap
- MIRM 2.5B
- LU 2.5B
- IPO Year
- MIRM 2019
- LU 2020
- Fundamental
- Price
- MIRM $51.12
- LU $2.82
- Analyst Decision
- MIRM Strong Buy
- LU Hold
- Analyst Count
- MIRM 9
- LU 2
- Target Price
- MIRM $66.22
- LU $2.98
- AVG Volume (30 Days)
- MIRM 351.2K
- LU 2.8M
- Earning Date
- MIRM 08-11-2025
- LU 08-20-2025
- Dividend Yield
- MIRM N/A
- LU N/A
- EPS Growth
- MIRM N/A
- LU N/A
- EPS
- MIRM N/A
- LU N/A
- Revenue
- MIRM $379,251,000.00
- LU $4,671,260,668.00
- Revenue This Year
- MIRM $36.76
- LU N/A
- Revenue Next Year
- MIRM $17.48
- LU N/A
- P/E Ratio
- MIRM N/A
- LU N/A
- Revenue Growth
- MIRM 69.31
- LU N/A
- 52 Week Low
- MIRM $36.20
- LU $2.13
- 52 Week High
- MIRM $54.78
- LU $4.15
- Technical
- Relative Strength Index (RSI)
- MIRM 50.28
- LU 47.45
- Support Level
- MIRM $50.92
- LU $2.68
- Resistance Level
- MIRM $52.63
- LU $3.41
- Average True Range (ATR)
- MIRM 1.49
- LU 0.13
- MACD
- MIRM -0.35
- LU 0.01
- Stochastic Oscillator
- MIRM 5.30
- LU 20.67
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.